Tarina Fe 1/20 Eq Kit
Product Images NDC 50102-228

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Tarina Fe 1/20 Eq (NDC 50102-228). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Afaxys Pharma, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Norethindroneethinyl Fig1)

A bar chart showing circulatory disease mortality rates per 100,000 woman years by age groups and smoking status among oral contraceptive users and controls. The chart compares mortality rates among ever-users (non-smokers and smokers) and controls (non-smokers and smokers) across four age groups: 15-24, 25-34, 35-44, and 45+. Mortality rates increase with age, with highest rates observed in ever-users who smoke aged 45 and older.*

FDA Label Image

Figure-2 (Norethindroneethinyl Fig2)

A forest plot chart comparing the effect estimates from multiple cohort studies on combined oral contraceptive (COC) use. The x-axis represents effect estimates ranging from -1.50 to 2.00. The chart includes two groups: "Ever COC vs. Never COC Use" and "Current COC use vs. Never-Use," with studies listed on the left and corresponding odds ratios (OR), hazard ratios (HR), and risk ratios (RR) shown as points with confidence intervals on the right.*

FDA Label Image

Figure-3 (Norethindroneethinyl Fig3)

An instructional diagram for the Tarina Fe 1/20 EQ kit showing a 4-week pill schedule with days of the week labeled Sunday through Saturday. Arrows guide the user to take pills from left to right each week, with emphasis on starting on Sunday or a specific day of the period. The diagram distinguishes between light yellow to yellow pills and brown pills.*

FDA Label Image

Figure-4 (Norethindroneethinyl Fig4)

An instructional diagram for the Tarina Fe 1/20 EQ kit tablets showing a weekly pill schedule. The diagram outlines a 4-week pill-taking cycle starting on Sunday, with empty circles arranged in rows labeled Week 1 through Week 4 and columns for each day of the week. Arrows indicate to take pills from left to right each week. Instructions note both Sunday starters and Day-1 starters, with additional guidance to take all light yellow to yellow pills before brown pills.*

FDA Label Image

Figure-5 (Norethindroneethinyl Fig5)

Packaging label for Tarina Fe 1/20 EQ kit by Afaxys Pharma, LLC. Contains norethindrone acetate and ethinyl estradiol tablets with ferrous fumarate. The 28-day regimen includes light yellow to yellow tablets containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol, and brown tablets containing 75 mg ferrous fumarate. Box includes one blister card with 28 tablets. NDC 50102-228.*

FDA Label Image

Norethindroneethinyl Fig6

Box packaging label for Tarina Fe 1/20 EQ kit by Afaxys Pharma, LLC. The label includes the proprietary name, active ingredients (norethindrone acetate, ethinyl estradiol, and ferrous fumarate), and states it is a 28 day regimen with three blister packs of 28 tablets each. The label also notes the manufacturing details including that it is a product of India and lists the NDC 50102-228-23. The design features blue and red wavy lines on a white background with text in blue and black.*

FDA Label Image

Chemical Structure (Norethindroneethinyl Str1)

Chemical structure of Norethindrone Acetate, an active ingredient in Tarina Fe 1/20 EQ. The structure shows the steroid-based molecular framework with labeled functional groups corresponding to the acetate and ethynyl substituents.*

FDA Label Image

Chemical Structure (Norethindroneethinyl Str2)

Chemical structure diagram of Ethinyl Estradiol, an active ingredient in Tarina Fe 1/20 EQ. The diagram shows the molecular arrangement with labeled chemical bonds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.